IIQ (ASX) Bard 1's B009 Type 3c Diabetes Test

Originally posted by 1lluminator ↑

Here's some hot BD1 news that hasn't hit the market yet (not that I've seen anyway) that should raise the SP when it's announced.

University of Liverpool signs option agreement with BARD1 for type 3C diabetes test

Reviewed by Emily Henderson, B.Sc.Jul 7 2021
The University of Liverpool has signed a two year option agreement with the Australian diagnostics company, BARD1 Life Sciences Ltd, for a type 3c diabetes (T3cDM) blood test. The test uses patented technology developed by researchers in the University of Liverpool's Institute of Systems, Molecular and Integrative Biology.
There are around 22.9 million new cases of new-onset diabetes diagnosed around the globe. T3cDM diabetes occurs in around 10 per cent of all new-onset diabetes cases. Currently, no test exists to identify T3cDM and it is most often misdiagnosed as type 2 diabetes (T2DM) and/or inappropriately managed. Approximately 10 in 100 people with T3cDM have underlying pancreatic cancer, with diabetes acting as an early warning sign for the presence of cancer.
Research by the University has reported that the combination of adiponectin and interleukin-1 receptor antagonist (IL-1Ra) showed a high diagnostic potential for distinction of T3cDM from T2DM (AUC = 0.90), with optimal sensitivity and specificity of 83.7% and 90.0% respectively.
Under the agreement, the University and BARD1 will evaluate two novel protein biomarkers that, in preliminary testing, have shown to accurately distinguish T3cDM from T2DM in individuals who are newly diagnosed with diabetes.
The agreement provides BARD1 with the option to licence the intellectual property for the development and commercialisation of a type 3c test on commercial terms. BARD1 will pay a non-material upfront option fee and support patent costs incurred by the University of Liverpool.
Professor of Molecular Oncology, Eithne Costello, heads up the project at the University. She is lead researcher on the UK-Early Detection Initiative (UK-EDI) which is collecting relevant samples which will allow validation of the T3cDM markers in larger sample sizes.
Related Stories

AI tool measures fat around the heart to predict a patient's risk of diabetes

Mother's gestational diabetes is an independent risk factor for fetal hypoxia during labor

New positive data on BCG’s ability to safely and significantly lower blood sugars

These findings have key implications for future pancreatic cancer screening because certain individuals with T3cDM are at increased risk of developing pancreatic cancer. Known risk factors for pancreatic cancer include smoking, obesity, diabetes and chronic pancreatitis (the predominate cause of T3cDM).
An accurate and reliable T3cDM test could be used to identify an at-risk population for a routine screening program for pancreatic cancer. Notably, there are no current screening tests available for pancreatic cancer and BARD1 is investigating two novel approaches for screening pancreatic cancer using its SubB2M and EXO-NET technologies, with the aim of introducing a world-first screening test for this killer disease resolving an important unmet need.
BARD1's Chief Scientific Officer Dr Peter French said: "In and of itself, a test for T3cDM could be a potential blockbuster diagnostic assay, as there would be a strong clinical case for using it to screen all individuals diagnosed with new-onset diabetes.
Those individuals that test positive for type 3c diabetes could then be placed in an enhanced surveillance program and screened annually for pancreatic cancer using the Company's specific pancreatic cancer tests currently in development. Clearly this approach could provide a significant improvement in outcomes for patients with both diseases."
Researchers developing this technology have been supported by grants from Pancreatic Cancer Action (PCA), Pancreatic Cancer UK (PCUK) and North West Cancer Research (NWCR). Further validation work is being supported by Cancer Research UK (CRUK).

https://www.news-medical.net/news/20210707/University-of-Liverpool-signs-option-agreement-with-BARD1-for-type-3C-diabetes-test.aspx

Expand

Well spotted, surely they need to announce this to market asap. tomorrow morn please

No.	Vol.	Price($)
2	41547	58.5¢

No.

Vol.

Price($)

41547

58.5¢

Price($)	Vol.	No.
61.0¢	13799	4

Price($)

Vol.

No.

61.0¢

13799

No.	Vol.	Price($)
2	41547	0.585
1	2269	0.580
1	5000	0.575
3	25481	0.565
3	28887	0.560

No.

Vol.

Price($)

41547

0.585

2269

0.580

5000

0.575

25481

0.565

28887

0.560

Price($)	Vol.	No.
0.610	13799	4
0.620	19392	3
0.625	1584	1
0.630	12205	2
0.650	4750	1

Price($)

Vol.

No.

0.610

13799

0.620

19392

0.625

1584

0.630

12205

0.650

4750

(20min delay)
Last 59.0¢		Change -0.010(1.67%)		Mkt cap ! $65.06M

Open	High	Low	Value	Volume
60.0¢	60.0¢	59.0¢	$17.47K	29.17K

Bard 1's B009 Type 3c Diabetes Test, page-2

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Nine's staff strike as Paris Olympic coverage begins

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

ASX Market Open: ASX200 to rise for Friday session | July 26

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Bard 1's B009 Type 3c Diabetes Test, page-2

Top Stories

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Nine's staff strike as Paris Olympic coverage begins

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

ASX Market Open: ASX200 to rise for Friday session | July 26

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News